In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

  title={In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.},
  author={Masahiro Takahata and Michio Shimakura and R. Hori and Kazuo Kizawa and Yozo Todo and Shinzaburo Minami and Yasuo Watanabe and Hirokazu Narita},
  journal={Antimicrobial agents and chemotherapy},
  volume={45 1},
T-3811, the free base of T-3811ME (BMS-284756), a new des-F(6)-quinolone, showed a potent in vitro activity (MIC at which 90% of the isolates tested are inhibited [MIC(90)], 0.0313 microg/ml) against Mycoplasma pneumoniae. The MIC(90) of T-3811 was 4-fold higher than that of clarithromycin but was 4- to 8-fold lower than those of trovafloxacin, gatifloxacin, gemifloxacin, and moxifloxacin and was 16- to 32-fold lower than those of levofloxacin, ciprofloxacin, and minocycline. In an experimental… CONTINUE READING
6 Citations
28 References
Similar Papers


Publications referenced by this paper.
Showing 1-10 of 28 references

In vitro activity of BAY 12 - 8039 , a new fluoroquinolone against mycoplasmas . An - timicrob

  • J. Child, F. Boswell J. Andrews, N. Brenwarld, R. Wise
  • Agents Chemother .
  • 1998

Similar Papers

Loading similar papers…